PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy

被引：0
|
作者：
Yixiang Zhu
Ye Zhang
Xingsheng Hu
Mingzhao Wang
Hongyu Wang
Yutao Liu
机构：
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Radiation Oncology
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
EGFR mutation or ALK rearrangement; Brain metastasis; Immune checkpoint inhibitor (ICI); Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3557 / 3566
页数：9
相关论文
共 50 条
  • [1] PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
    Zhu, Yixiang
    Zhang, Ye
    Hu, Xingsheng
    Wang, Mingzhao
    Wang, Hongyu
    Liu, Yutao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (12) : 3557 - 3566
  • [2] PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
    Liu, Y.
    Zhu, Y.
    Hu, X.
    Wang, M.
    Zhang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S364 - S364
  • [3] Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC
    Landi, Lorenza
    Cappuzzo, Federico
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (06) : 579 - 587
  • [4] Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
    Wu, Lige
    Zou, Zihua
    Li, Yan
    Hao, Xuezhi
    Ying, Jianming
    Li, Junling
    Xing, Puyuan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [5] Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
    Chotai, S.
    Schmid, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1089 - S1089
  • [6] Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC
    Somasundaram, Aswin
    Socinski, Mark A.
    Burns, Timothy F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (18) : 2693 - 2708
  • [7] The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC
    Liao, Dehua
    Yu, Lun
    Chen, Shanshan
    Liu, Ni
    Tang, Jingyi
    Yang, Nong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 116
  • [8] COST OF MANAGING BRAIN METASTASES IN PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC WITH FIRST-LINE ALK TYROSINE KINASE INHIBITORS (TKIS) IN CHINA
    Hu, B.
    Xue, J.
    Siman, L.
    Duan, J.
    Luan, L.
    Le, H.
    Dong, P.
    Li, H.
    VALUE IN HEALTH, 2024, 27 (12) : S101 - S101
  • [9] Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second-Generation ALK-TKIs
    Zou, Z.
    Xing, P.
    Hao, X.
    Li, Y.
    Ying, J.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S400 - S400
  • [10] Radiation Necrosis Risk in NSCLC Patients Receiving EGFR TKIs or ALK Inhibitors
    De Vis, J. B.
    Jean-Baptiste, S.
    Abernathy, K.
    Pham, H. H.
    Cass, A. S.
    Osmundson, E. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E50 - E51
12345